VMT Scientific Inc. Announces Its Globally Patented Breakthrough VasCir(TM) Technology

Nov 02, 2005, 00:00 ET from VMT Scientific, Inc.

    LAS VEGAS, Nov. 2 /PRNewswire-FirstCall/ -- VMT Scientific Inc.
 (OTC: VMTF) announces its globally patented breakthrough technology that may
 make the need for Peripheral Vascular Disease (PVD) and Diabetic associated
 amputations obsolete.  Its technology, the VasCir(TM) system is designed to
 re-establish microvascularization and Tissue Histogenesis.
     Engineering and the Science: VMT Scientific Inc. has patented a unique
 design of sophisticated negative pressure technology that leads to the first
 controlled and repeatable method of soft tissue histogenesis.  The technology
 also has identified several additional unique medical applications and is
 protected both domestically and internationally by patents.  The patented
 methodology and technology is focused on the values perceived in the areas of
 neurology, vascular disease, pediatric medicine and reconstructive/aesthetic
     VMT Scientific Inc. is focused to mature this technology through
 additional objective evidence with clinical trials.  The clinical data will be
 used to file for clearance with the FDA for the therapeutical treatment of
 "Diabetic Neuropathy and PVD."  Upon clearance, VMT Scientific Inc. will make
 available license rights of the VasCir(TM) to manufacturers and distribution
 organizations worldwide.
      The Technological FACTS are:
      * Tissue histogenesis is well known and documented.
      * The independent production of new tissue is produced through proper
        stimulation and the benefits have been shown to last for years.
      * Damaged tissues respond with accentuated healing capabilities.
      * The VasCir(TM) system has demonstrated its ability to "non-invasively"
        control blood flow with increases up to 300%.
      * DYNAMICALY controlled increases in blood flow have a dramatic immune
        system response.
      * DYNAMICALY controlled increases in blood flow to areas previously
        ischemic facilitates the regeneration of neurological tissues.
     Please visit VMT Scientific, Inc.'s Web site for more information:
     This Press Release contains forward-looking statements within the meaning
 of the "safe harbor" provisions of the Private Securities Litigation Reform
 Act of 1995.  You should not place undue reliance on these forward-looking
 statements.  These statements involve risks and uncertainties that could cause
 actual results to differ materially from those suggested in the forward-
 looking statements, particularly those risks and uncertainties inherent in the
 process of developing, manufacturing and distributing medical products and
 Clinical trials.  Factors that may cause such a difference include risks
 related to VMT Scientific Inc.'s limited operating history, risks associated
 with completing development and obtaining FDA medical approvals, successful
 patent protection and prosecution, successful sale of licensed technology
 nationally or internationally.  VMT Scientific technology will not meet with
 market acceptance, the risk of future warranty and product liability claims,
 the uncertainty of VMT Scientific Inc.'s future access to capital to sustain
 operations, achieve profitability or continue as a going concern, the failure
 by VMT Scientific Inc.'s to secure and maintain relationships with suppliers,
 manufacturers and other third parties, reliance on key employees, and
 dependence on intellectual property.  World events, national economy and/or
 other conditions and circumstances beyond our control.  Further information on
 the factors and risks that could affect VMT Scientific Inc.'s business,
 financial condition and results of operations.  These forward-looking
 statements are based on information and management's expectations as of the
 date hereof.  Future results may differ materially from our current
 expectations.  VMT Scientific Inc.'s disclaims any intent or obligation to
 update whose forward-looking statements.
                 "Saving feet and limbs is what it's all about"
                            Says VMT Scientific Inc.

SOURCE VMT Scientific, Inc.